Condition: Esophageal Adenocarcinoma · Gastric Cancer · Pancreatic Cancer · Sponsor: Masaryk Memorial Cancer Institute
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.
This description comes directly from the study's public registry record.
Martina Lojová, PhD · +420543136232 · martina.lojova@mou.cz
Tereza Štěpánková, PhD · +420543136223 · tereza.stepankova@mou.cz
Always discuss trial participation with your own doctor first.
| Masaryk Memorial Cancer Institute | Brno, Czechia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07660627